Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fovista + Anti-VEGF in Wet AMD
NCT01940887Phase 3Terminated
- Sponsor
- IVERIC bio
- Start
- May 2014
- Primary completion
- Jun 2017
- Modality
- Polymer-based Nanoparticles, RNA Aptamers, DNA Aptamers
- Countries
- 22
01
Overview
A Phase 3 trial of pegpleranib in neovascular age-related macular degeneration (NVAMD), sponsored by IVERIC bio. Started May 2014; status: terminated.
02
Drugs
pegpleranib
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT01940887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01940887.